ClinicalTrials.gg
CompletedNCT04232423OLN-EMEUpdated Jan 21, 2022

Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

A Phase 3 interventional study of Olanzapine 10 Mg ORAL TABLET and Olanzapine 5 Mg ORAL TABLET in Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis, sponsored by Rajavithi Hospital. Completed at 1 site in Thailand. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-21.

Sponsored by Rajavithi Hospital · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo

Read the detailed description

A double-blind, placebo-controlled, randomized crossover trial

02

Conditions studied

  • Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis

Browse trials for

Keywords

  • Olanzapine
  • Chemotherapy-induced nausea and vomiting
  • Carboplatin
  • Gynecologic cancer
03

In context

Vomiting

793 studies on the registry are indexed under Vomiting; 99 are open to participants now.

This study's enrollment of 90 is below the median of 103 across 673 interventional studies indexed under Vomiting.

Browse Vomiting studies →

Lead sponsor

Rajavithi Hospital is the lead sponsor of 46 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with gynecological cancer receiving carboplatin-based chemotherapeutic regimen
  • performance status 0-1
  • Normal bone marrow, liver, and renal functions
  • Can speak and write in Thai language

Exclusion criteria

Exclusion Criteria:

  • Women with nausea or vomiting prior to chemotherapeutic administration
  • Pregnant women
  • Women with active infection
  • Women with bowel obstruction
  • Women with symptomatic
  • Women who received dopamine receptor antagonists within 1 week before chemotherapeutic administration
  • Women who received within 1 week before chemotherapeutic administration
  • Women with past history of chemotherapy or radiotherapy
  • Women with psychiatric disorders
  • Women with poor controlled diabetes mellitus
  • Women who received anticonvulsant medication
  • Women with history of neuroleptic malignant syndrome
  • Women with history of olanzapine allergy
  • Women with history of lactose intolerance
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    OLN 0-5-10

    Placebo tablet in chemotherapy cycle 1, olanzapine 5 mg tablet in chemotherapy cycle 2, and olanzapine 10 mg tablet in chemotherapy cycle 3

    Drug: Olanzapine 10 Mg ORAL TABLET · Drug: Olanzapine 5 Mg ORAL TABLET · Drug: Placebo ORAL TABLET

  • Experimental
    OLN 5-10-0

    Olanzapine 5 mg tablet in chemotherapy cycle 1, olanzapine 10 mg tablet in chemotherapy cycle 2, and placebo tablet in chemotherapy cycle 3

    Drug: Olanzapine 10 Mg ORAL TABLET · Drug: Olanzapine 5 Mg ORAL TABLET · Drug: Placebo ORAL TABLET

  • Experimental
    OLN 10-0-5

    Olanzapine10 tablet in chemotherapy cycle 1, placebo tablet in chemotherapy cycle 2, and olanzapine 5 mg tablet in chemotherapy cycle 3

    Drug: Olanzapine 10 Mg ORAL TABLET · Drug: Olanzapine 5 Mg ORAL TABLET · Drug: Placebo ORAL TABLET

Interventions

  • * Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1) * Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

  • * Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1) * Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

  • DrugPlacebo ORAL TABLET

    * Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1) * Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

06

What researchers measure

Primary outcomes

  1. Complete response rate of chemotherapy-induced nausea and vomiting prophylaxis

    No breakthrough vomiting and no using rescue therapy

    Time frame: 5 days after chemotherapeutic administration

Secondary outcomes

  1. Episodes of vomiting

    Time frame: 5 days after chemotherapeutic administration

  2. Severity of nausea

    Time frame: 5 days after chemotherapeutic administration

  3. Use of rescue drug

    using of rescue anti-emetic medication

    Time frame: 5 days after chemotherapeutic administration

  4. Quality of life associated with nausea and vomiting measured using Functional Living Index-Emesis (FILE)

    Time frame: 5 days after chemotherapeutic administration

07

Study locations

1 site
  • Rajavithi hospital
    Bangkok, 10400, Thailand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jun 2021, 15 months.

Of 37 non-industry phase 3 interventional studies under Vomiting, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 15 months is below that.

Counting every sponsor, half of 56 studies reached it within 21 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2020
First posted
Jan 18, 2020
StartActual
Mar 1, 2020
Primary completionActual
Jun 30, 2021
CompletionActual
Sep 30, 2021
Last update
Jan 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04232423
Lead sponsor
Rajavithi Hospital
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Mar 1, 2020
Primary completion
Jun 30, 2021
Completion
Sep 30, 2021
Last update
Jan 21, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion